Advertisement

Journal of Inherited Metabolic Disease

, Volume 34, Issue 2, pp 309–313 | Cite as

Altering the balance between healthy and mutated mitochondrial DNA

  • Paul M. Smith
  • Robert N. Lightowlers
Mitochondrial Medicine

Abstract

Pathogenic mutations of the mitochondrial genome are frequently found to co-exist with wild-type mtDNA molecules, a state known as heteroplasmy. In most disease cases, the mutation is recessive with manifestation of a clinical phenotype occurring when the proportion of mutated mtDNA exceeds a high threshold. The concept of increasing the ratio of healthy to mutated mtDNA as a means to correcting the biochemical defect has received much attention. A number of strategies are highlighted in this article, including manipulation of the mitochondrial genome by antigenomic drugs or restriction endonucleases, zinc finger peptide-targeted nucleases and exercise-induced gene shifting. The feasibility of these approaches has been demonstrated in a number of models, however more work is necessary before use in human patients.

Keywords

Satellite Cell Triphenyl Phosphonium Leigh Disease Pearson Syndrome ScaI Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

ATP

Adenosine 5′-triphosphate

LHON

Leber hereditary optic neuropathy

MERRF

Myoclonic epilepsy with ragged red fibres

mtDNA

Mitochondrial DNA

NARP

Neurogenic muscle weakness ataxia and retinitis

OXPHOS

Oxidative phosphorylation

PNAs

Peptide nucleic acids

ZPFs

Zinc finger peptides

References

  1. Anderson S, Bankier AT, Barrell BG et al (1981) Sequence and organization of the human mitochondrial genome. Nature 290:457–465PubMedCrossRefGoogle Scholar
  2. Bacman SR, Williams SL, Hernandez D, Moraes CT (2007) Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model. Gene Ther 14:1309–1318PubMedGoogle Scholar
  3. Bayona-Bafaluy MP, Blits B, Battersby BJ, Shoubridge EA, Moraes CT (2005) Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease. Proc Natl Acad Sci USA 102:14392–14397PubMedCrossRefGoogle Scholar
  4. Chinnery PF, Taylor RW, Diekert K, Lill R, Turnbull DM, Lightowlers RN (1999) Peptide nucleic acid delivery to human mitochondria. Gene Ther 6:1919–1928PubMedCrossRefGoogle Scholar
  5. Chinnery PF, Johnson MA, Wardell TM et al (2000) The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol 48:188–193PubMedCrossRefGoogle Scholar
  6. Clark KM, Bindoff LA, Lightowlers RN et al (1997) Reversal of a mitochondrial DNA defect in human skeletal muscle. Nat Genet 16:222–224PubMedCrossRefGoogle Scholar
  7. Dassa EP, Dufour E, Goncalves S et al (2009) Expression of the alternative oxidase complements cytochrome c oxidase deficiency in human cells. EMBO Mol Med 1:30–36PubMedCrossRefGoogle Scholar
  8. King MP, Attardi G (1988) Injection of mitochondria into human cells leads to a rapid replacement of the endogenous mitochondrial DNA. Cell 52:811–819PubMedCrossRefGoogle Scholar
  9. Manfredi G, Gupta N, Vazquez-Memije ME et al (1999) Oligomycin induces a decrease in the cellular content of a pathogenic mutation in the human mitochondrial ATPase 6 gene. J Biol Chem 274:9386–9391PubMedCrossRefGoogle Scholar
  10. McFarland R, Taylor RW, Turnbull DM (2007) Mitochondrial disease–its impact, etiology, and pathology. Curr Top Dev Biol 77:113–155PubMedCrossRefGoogle Scholar
  11. Minczuk M, Papworth MA, Kolasinska P, Murphy MP, Klug A (2006) Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase. Proc Natl Acad Sci USA 103:19689–19694PubMedCrossRefGoogle Scholar
  12. Minczuk M, Papworth MA, Miller JC, Murphy MP, Klug A (2008) Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucleic Acids Res 36: 3926–38Google Scholar
  13. Muratovska A, Lightowlers RN, Taylor RW et al (2001) Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res 29:1852–1863PubMedCrossRefGoogle Scholar
  14. Murphy JL, Blakely EL, Schaefer AM et al (2008) Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 131:2832–2840PubMedCrossRefGoogle Scholar
  15. Ross GF, Smith PM, McGregor A, Turnbull DM, Lightowlers RN (2003) Synthesis of trifunctional PNA-benzophenone derivatives for mitochondrial targeting, selective DNA binding, and photo-cross-linking. Bioconjug Chem 14:962–966PubMedCrossRefGoogle Scholar
  16. Santra S, Gilkerson RW, Davidson M, Schon EA (2004) Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol 56:662–669PubMedCrossRefGoogle Scholar
  17. Shoubridge EA, Johns T, Karpati G (1997) Complete restoration of a wild-type mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation and mitochondrial encephalomyopathy. Hum Mol Genet 6:2239–2242PubMedCrossRefGoogle Scholar
  18. Smith PM, Ross GF, Taylor RW, Turnbull DM, Lightowlers RN (2004) Strategies for treating disorders of the mitochondrial genome. Biochim Biophys Acta 1659:232–239PubMedCrossRefGoogle Scholar
  19. Spelbrink JN, Zwart R, Van Galen MJ, Van den Bogert C (1997) Preferential amplification and phenotypic selection in a population of deleted and wild-type mitochondrial DNA in cultured cells. Curr Genet 32:115–124PubMedCrossRefGoogle Scholar
  20. Srivastava S, Moraes CT (2001) Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. Hum Mol Genet 10:3093–3099PubMedCrossRefGoogle Scholar
  21. Srivastava S, Diaz F, Iommarini L, Aure K, Lombes A, Moraes CT (2009) PGC-1alpha/beta induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders. Hum Mol Genet 18:1805–1812PubMedCrossRefGoogle Scholar
  22. Taivassalo T, Fu K, Johns T, Arnold D, Karpati G, Shoubridge EA (1999) Gene shifting: a novel therapy for mitochondrial myopathy. Hum Mol Genet 8:1047–1052PubMedCrossRefGoogle Scholar
  23. Taivassalo T, Shoubridge EA, Chen J et al (2001) Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann Neurol 50:133–141PubMedCrossRefGoogle Scholar
  24. Taivassalo T, Gardner JL, Taylor RW et al (2006a) Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain 129:3391–3401PubMedCrossRefGoogle Scholar
  25. Taivassalo T, Gardner JL, Taylor RW et al (2006b) Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain 129:3391–3401PubMedCrossRefGoogle Scholar
  26. Tanaka M, Borgeld HJ, Zhang J et al (2002) Gene therapy for mitochondrial disease by delivering restriction endonuclease Smal into mitochondria. J Biomed Sci 9:534–541PubMedGoogle Scholar

Copyright information

© SSIEM and Springer 2010

Authors and Affiliations

  1. 1.Mitochondrial Research Group, Institute of Ageing and HealthMedical SchoolNewcastle upon TyneUK

Personalised recommendations